Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
European Society for Medical Oncology (ESMO)
European Society for Medical Oncology (ESMO)
The
European Society for Medical Oncology
(
ESMO
) is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 150 countries worldwide, ESMO was founded in 1975.
Efficacy and Safety of Front-Line Veliparib and Paclitaxel Weekly versus Every 3 Weeks in the VELIA Study
ESMO 2020
In patients with newly diagnosed high-grade serous ovarian cancer, dose-dense weekly paclitaxel was associated with longer progression-free survival and higher frequency of grade 3/4 adverse events, including hematologic toxicities, versus paclitaxel given every 3 weeks.
Read More ›
Timing of Adverse Events During Maintenance Treatment with Rucaparib for Recurrent Ovarian Cancer in Phase 3 Study
ESMO 2020
The phase 3 ARIEL3 study investigated rucaparib as maintenance therapy in patients with recurrent ovarian cancer. An exploratory safety analysis found time to onset of nonhematologic treatment-emergent adverse events was 1 month, 2 months for anemia, and 3 months for decreased hemoglobin.
Read More ›
Response to Olaparib Monotherapy in Relapsed Ovarian Cancer by HRR Gene Mutational Status and HRD Scarring Analysis
ESMO 2020
A phase 2, randomized study of patients with platinum-resistant relapsed ovarian cancer assessed overall response to olaparib monotherapy compared with standard-of-care chemotherapy. Olaparib was effective in platinum-resistant and platinum-sensitive patients with and without homologous recombination repair (
HRR
) gene alterations.
Read More ›
Olaparib Maintenance Therapy in Clinical Practice: Quality-of-Life Interim Results of the C-PATROL Study in Ovarian Cancer
ESMO 2020
An observational study of hospitalized patients and patients in outpatient treatment facilities being treated with olaparib as maintenance therapy for relapsed
BRCA
-mutated ovarian cancer following platinum-based chemotherapy reveals preservation of health-related quality of life in interim study results.
Read More ›
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012
ESMO 2020
In patients with advanced ovarian cancer, niraparib resulted in similar efficacy, safety, and quality-of-life outcomes for patients 65 years of age and those ≥65 years of age. An individualized starting dose resulted in fewer grade ≥3 thrombocytopenia events than a fixed starting dose.
Read More ›
Phase 2 Trial of Olvi-Vec in Heavily Pretreated Platinum-Resistant/Refractory Ovarian Cancer
ESMO 2020
The VIRO-15 trial of intraperitoneal Olvi-Vec virus infusion followed by intravenous carboplatin-doublet ± bevacizumab in pretreated platinum-resistant/refractory ovarian cancer patients revealed promising response rates and progression-free survival. Safety results were consistent with a previous phase 1b trial of this agent.
Read More ›
Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
ESMO 2020
For patients with non-germline
BRCA
-mutated platinum-sensitive relapsed ovarian cancer, the triple combination of olaparib, durvalumab, and bevacizumab demonstrated a promising 24-week disease control rate and safety profile while the combination of olaparib plus durvalumab did not meet the prespecified efficacy target.
Read More ›
Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer
ESMO 2020
The SOLO1 trial studied maintenance olaparib in newly diagnosed patients with advanced
BRCA
-mutated ovarian cancer. This analysis assesses outcomes 5 years after the last patient enrolled in the trial and represents the longest follow-up for a PARP inhibitor trial in this setting.
Read More ›
Results from the GEICO1601-ROLANDO Phase 2 Trial Evaluating Combination of Olaparib and PLD in Platinum-Resistant Ovarian Cancer
ESMO 2020
In patients with platinum-resistant ovarian cancer, 46% treated per protocol with olaparib and pegylated liposomal doxorubicin (PLD) achieved 6-month progression-free survival regardless of
BRCA
status. Adverse events were less frequent with a reduction of the PLD dose.
Read More ›
A Network Meta-Analysis Comparing Efficacy of First-Line Maintenance PARP Inhibitors
ESMO 2020
This network meta-analysis comparing first-line maintenance therapies in advanced ovarian cancer revealed that PARP inhibitors result in better outcomes than antiangiogenic agents. Individual PARP inhibitors vary in efficacy and adverse events across mutation subtypes.
Read More ›
Page 2 of 9
1
2
3
4
5
6
7
8
9
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us